The short answer
The evidence checked does not establish that Ganoderma supplements change entrectinib effectiveness or absorption. Have the exact supplement reviewed before using it during cancer treatment.
What this answer covers
The current supplement entry is Ganoderma at genus level. The original experiment studied Ganoderma lucidum, a specific species and solvent extract, not every Ganoderma product or human entrectinib co-use.
- Supplement or preparation
- Ganoderma
- Medication ingredient
- entrectinib
Check the exact treatment
This review concerns oral entrectinib in ROZLYTREK capsules or oral pellets for selected gene-fusion cancers. The medicine produces an active metabolite called M5. Follow the instructions for the prescribed formulation; a change in parent-drug levels does not automatically describe total active exposure.
What the supplement evidence shows
An original experiment used a dichloromethane mushroom extract in liver-enzyme tests and rats. Rat probe-drug exposure changed at the tested dose. These were not patients, and the solvent extract and dose cannot be equated with an ordinary reishi supplement or entrectinib co-use.
Keep enzyme effects separate from treatment outcomes
Entrectinib is sensitive to some CYP3A inhibitors and inducers, but potency and preparation matter. Clinical drug-interaction studies measured entrectinib and its active M5 metabolite separately. They do not demonstrate that this supplement changes cancer control, total active exposure or toxicity.
Review the whole product
Bring the supplement name, species, dose and complete ingredient list to the oncology pharmacist. Mushroom powders, spores and solvent extracts can differ. Do not use a supplement to boost treatment or invent a spacing interval; the team should assess the actual product.
Evidence and practical considerations
Absorption & effectiveness
The current exact-pair claim remains insufficient; drug metabolic susceptibility alone does not turn a botanical laboratory or other-drug finding into a measured clinical interaction.
- Exact scope
- The current supplement entry is Ganoderma at genus level. The original experiment studied Ganoderma lucidum, a specific species and solvent extract, not every Ganoderma product or human entrectinib co-use. with RxNorm 2197862 IN entrectinib. Current exact oral product: ROZLYTREK oral entrectinib capsules and pellets. Salt/formulation named explicitly; no transfer to unrelated drugs or routes.
- Medication form and route
- Oral
What remains uncertain
- No exact entrectinib co-use clinical evidence identified. Rat/microsome experiment cannot establish human inhibition strength or bioavailability. Current genus-level entry does not verify the species in an individual product.
Factors that may matter: Exact oral formulation and supplement preparation; Drug exposure versus clinical outcomes; Dose, duration and other medicines; Individual monitoring plan.
Read the supporting source summaries
Source 1: Current original prescribing information
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Patients prescribed the exact oral formulation.
Avoid moderate/strong CYP3A inducers/inhibitors; parent drug and M5 exposure must be distinguished.
How this applies: RxNorm 2197862 IN entrectinib. Current exact oral product: ROZLYTREK oral entrectinib capsules and pellets. Salt/formulation named explicitly; no transfer to unrelated drugs or routes.
Exact current oral product source, not a clinical trial of every supplement. Formulation, dose, population and mechanism remain explicit.
Source 2: Original clinical research
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: Healthy subjects and patients in separate clinical studies.
CYP3A inhibitors/inducers affected entrectinib and active M5 differently; parent exposure cannot represent the active sum automatically.
How this applies: Exact reported preparation, population and endpoints; transfer to entrectinib explicitly limited.
Original body; drug probes, not any named botanical, and exact experimental dose/form retained.
Source 3: Original preclinical research
pmc.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: Human liver microsomes and rats, not clinical participants.
Inhibited selected CYP assays and altered rat probe-drug exposure.
How this applies: Mechanistic lead only, insufficient exact clinical interaction.
Not entrectinib; solvent extract and animal dose not equivalent to marketed mushroom supplements.
Source 4: Medication terminology
rxnav.nlm.nih.gov · Source check Sep 10, 2026
Population: Terminology.
entrectinib is IN.
How this applies: Exact ingredient.
Not clinical evidence.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Research summary published | |
| Article prepared | |
| Sources checked and article drafted. |
Article revision: 7ed74a2b7d192da0
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.